DataMeds AI Regains Compliance With Nasdaq Equity Rule

DataMeds AI, Inc. (NASDAQ: MEDS) has regained compliance with Nasdaq Listing Rule 5550(b)(1) after confirming its stockholders' equity exceeded the required $2.5 million. The company had previously received a delisting notice on April 13, 2026, due to failing to meet the minimum bid price and stockholder equity requirements. Nasdaq notified DataMeds on June 9, 2026, that it had regained bid-price compliance, allowing additional time to meet the equity requirement. Compliance was confirmed on October 19, 2026, but failure to maintain compliance in future reports may lead to delisting.